Blocking caspase and/or fasl for preventing fataloutcome in covid-19 patients

Herein the inventors demonstrated that CD4 and CD8 T cells from COVID-19 patients are more prone to undergo death and that blocking caspase activation prevents T cell death. Furthermore, they found that higher levels of soluble FasL in the plasma of COVID-19 individuals is associated with higher levels of T cell death. This propensity of CD4 T cells to die as well of FasL levels is associated with lower specific SARS-CoV-2 IgG response. The presence of higher levels of soluble caspase-1 in the plasma and of IL-18 also indicated an inflammasome activation pathway, which can be link with several endothelial biomarkers of cell damage. Therefore, strategy aims to block caspase and/or FasL could be beneficial for restoring full immune competent immune cells and preventing fatal outcome in COVID-19 patients.

Keywords: COVID19, Severe form prediction, Companion diagnostic
Patent Application number: EP20 306 543.8 on 11/12/20

Reference:

BIO20529-D1

Business Developper
contact
Pierre MAZOT
Pierre MAZOT
Business Developer
Patent filling date: 2020-12-11

You might also be interested in